@FierceMedDev: ICYMI: PatientsLikeMe and Biogen reveal positive data from wearable device study for MS. Report | Follow @FierceMedDev
@VarunSaxena2: Alcon intraocular lens gets FDA's stringent PMA approval. News | Follow @VarunSaxena2
@EmilyWFierce: Focus Diagnostics gets FDA nod for rapid strep test. FierceDiagnostics article | Follow @EmilyWFierce
> Weight Watchers is starting a randomized control trial to see if a connected scale will aid in its online weight loss program. Story
> Mallinckrodt ($MNK) has completed its previously announced acquisition of nitric oxide focused Ikaria for about $2.3 billion. More
> MRI-guided radiation therapy player ViewRay has withdrawn its IPO in which it planned to raise $52 million. More
> Medtronic ($MDT) has disclosed further clinical data for its Solitaire thrombectomy stent to reduce disability in stroke patients. More
Biotech News
@FierceBiotech: EuroBiotech Report: Israel awaits $250M fund, ThromboGenics spins out oncology asset, MolMed licenses CAR-T. More | Follow @FierceBiotech
@JohnCFierce: Trending: The flimsy case for a miracle ALS drug collapses under expert scrutiny. Editor's corner | Follow @JohnCFierce
> AstraZeneca's ($AZN) '$3B' lung cancer drug impresses in a Phase II race with Clovis. More
> The FDA calls on Genervon to release data from controversial ALS study. Story
> Atlas Venture unveils a $280M pure play biotech startup fund. Report
Pharma News
@FiercePharma: GlaxoSmithKline to close Pittsburgh office, consolidate consumer ops in New Jersey. News | Follow @FiercePharma
@EricPFierce: Sanofi Pasteur is adding a fill/finish facility at US site as part of dengue vax plan. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: AbbVie moves closer to Japan's crowded hep C field with priority review nod. Article | Follow @CarlyHFierce
> Analyst: Vivus ($VVUS) generic threats a positive for obesity market. More
> Bad news, Teva ($TEVA)--Sandoz has an FDA nod for generic Copaxone. But when will it launch? News
> Bristol-Myers Squibb ($BMS), focused on immuno-oncology, turns Erbitux over to Eli Lilly ($LLY). Article